Identification of rearranged sequences of HPV16 DNA in precancerous and cervical cancer cases

Tsakogiannis, D.; Bletsa, Magda; Kyriakopoulou, Zaharoula; Dimitriou, Tilemachos G.; Kotsovassilis, Constantin; Panotopoulou, Efstathia; Markoulatos, Panayotis

doi:10.1016/j.mcp.2015.11.004

Cited by 8 publications

(13 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since then, many PCR-based detection methods have been developed to explore the genomic interaction between the virus and the host. For instance, ligation-mediated chain reaction (DIPS-PCR) [62][63][64][65][66][67][68][69] and restriction site-PCR (RS-PCR) [63,[70][71][72][73] were used to profile HPV integration sites on the DNA level, while the amplification of papillomavirus oncogene transcripts (APOT) assay was used on the RNA level [62,65,[74][75][76][77][78][79][80]. Although these methods were generally labor-intensive and time-consuming, the data lay the foundation for the understanding of the HPV integration pattern and its role in cervical carcinogenesis.…”

Section: Hpv Integrationmentioning

confidence: 99%

The precision prevention and therapy of HPV‐related cervical cancer: new concepts and clinical implications

2018

Cancer Medicine

256

140

View full text Add to dashboard Cite

Cervical cancer is the third most common cancer in women worldwide, with concepts and knowledge about its prevention and treatment evolving rapidly. Human papillomavirus (HPV) has been identified as a major factor that leads to cervical cancer, although HPV infection alone cannot cause the disease. In fact, HPV‐driven cancer is a small probability event because most infections are transient and could be cleared spontaneously by host immune system. With persistent HPV infection, decades are required for progression to cervical cancer. Therefore, this long time window provides golden opportunity for clinical intervention, and the fundament here is to elucidate the carcinogenic pattern and applicable targets during HPV‐host interaction. In this review, we discuss the key factors that contribute to the persistence of HPV and cervical carcinogenesis, emerging new concepts and technologies for cancer interventions, and more urgently, how these concepts and technologies might lead to clinical precision medicine which could provide prediction, prevention, and early treatment for patients.

show abstract

Section: Hpv Integrationmentioning

confidence: 99%

The precision prevention and therapy of HPV‐related cervical cancer: new concepts and clinical implications

2018

Cancer Medicine

256

140

View full text Add to dashboard Cite

show abstract

“…These changes contain the conjunction of different fragments of HPV16 DNA with inverted orientation. These sequence forms were primarily described in the Caski cell line (Refs 26, 27), while a more recent analysis revealed their presence in precancerous and cervical cancer cases, as well (Ref. 27).…”

Section: Integration Of Hpv Dnamentioning

confidence: 99%

“…The method is performed through a first round of PCR that utilises HPV site-specific primers in conjunction with an individual RSO primer. Subsequently, a second round of nested PCR is conducted by using as template an aliquot of the first RS-PCR, a nested primer specific for HPV DNA and the same RSO (Refs 27, 136, 137). The final product is subjected to sequencing in order to determine HPV-DNA sequences adjoining cellular sequences (Table 2).…”

Section: Assays For the Identification Of Hpv-dna Physical Statusmentioning

confidence: 99%

“…Over the last decades several studies have focused on the analysis of the physical status of HPV DNA considering its causal association with cervical cancer development. The identification of integrated viral genomes in clinical samples is regarded as a valuable prognostic tool that facilitates the accurate prediction of cervical cancer development (Refs 22, 23, 24, 25, 27, 30, 31). In the present review, we describe molecular approaches for HPV-DNA detection and genotyping for intra-lesion analyses and review molecular assays for the determination of HPV-DNA physical status.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Molecular approaches for HPV genotyping and HPV-DNA physical status

Tsakogiannis

Gartzonika

Levidiotou-Stefanou

et al. 2017

Expert Rev. Mol. Med.

Self Cite

View full text Add to dashboard Cite

Persistent infection with high-risk human papillomavirus (HPV) genotypes is the leading cause of cervical cancer development. To this end several studies have focused on designing molecular assays for HPV genotyping, which are considered as the gold standard for the early diagnosis of HPV infection. Moreover, the tendency of HPV DNA to be integrated into the host chromosome is a determining event for cervical oncogenesis. Thus, the establishment of molecular techniques was promoted in order to investigate the physical status of the HPV DNA and the locus of viral insertion into the host chromosome. The molecular approaches that have been developed recently facilitate the collection of a wide spectrum of valuable information specific to each individual patient and therefore can significantly contribute to the establishment of a personalised prognosis, diagnosis and treatment of HPV-positive patients. The present review focuses on state of the art molecular assays for HPV detection and genotyping for intra-lesion analyses, it examines molecular approaches for the determination of HPV-DNA physical status and it discusses the criteria for selecting the most appropriate regions of viral DNA to be incorporated in HPV genotyping and in the determination of HPV-DNA physical status.

show abstract

“…Human papillomaviruses (HPVs) are a group of non-enveloped viruses with a double-stranded DNA [ 1 , 2 ], which mainly infect epithelial cells and can further induce a variety of benign and malignant hyperplasia [ 3 ]. The high-risk, oncogenic HPV types are related to invasive cervical cancer and other genital carcinomas; whereas the low-risk HPVs cause anogenital warts [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Development and characterization of an HPV18 detection kit using two novel HPV18 type-specific monoclonal antibodies

Zhang

et al. 2018

Diagn Pathol

View full text Add to dashboard Cite

BackgroundHPV 18 is one of the most prevalent oncogenic types, only second to HPV 16, and included in the licensed vaccines on the market. In this study, we describe the production and characterization of a panel of monoclonal antibodies (mAb) to HPV18.MethodsThe immunocompetence of 1B1 and 4C2 mAbs for HPV L1 protein was evaluated by SDS-PAGE analysis, neutralization assays, affinity identification, and ELISA. The 1B1 and 4C2 genes were sequenced and analyzed. Finally, the detection kit with the two mAbs was assessed for linearity, repeatability and specificity.ResultsBoth mAbs specifically recognized HPV18 L1 and virus-like particles (VLPs). These mAbs are conformation-neutralizing antibodies that have high affinity and type specificity. Based on these characteristics of these mAbs, we developed an ELISA kit for specifically detecting HPV 18 antigen. We showed that this kit displayed good linearity, repeatability and sensitivity for detecting HPV18 L1 pentamer and HPV18 VLP.ConclusionsWe characterized two monoclonal neutralizing antibodies for HPV L1 protein, and developed an ELISA kit for specifically detecting HPV 18 antigen. This newly developed kit can be used to monitor the potency of HPV vaccines throughout the entire production process as well as preliminary analysis of HPV18 infections.

show abstract

Identification of rearranged sequences of HPV16 DNA in precancerous and cervical cancer cases

Cited by 8 publications

References 33 publications

The precision prevention and therapy of HPV‐related cervical cancer: new concepts and clinical implications

The precision prevention and therapy of HPV‐related cervical cancer: new concepts and clinical implications

Molecular approaches for HPV genotyping and HPV-DNA physical status

Development and characterization of an HPV18 detection kit using two novel HPV18 type-specific monoclonal antibodies

Contact Info

Product

Resources

About